AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03751982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Electrical Neuromodulation (TES)
Description: TES phase-aligned with slow waves or not
Study NCT02150863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrapulse Carbon Dioxide Laser
Study NCT02150863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellutome epidermal harvesting system
Study NCT02624856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
Study NCT02624856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus dexamethasone
Description: Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
Study NCT03323255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repeated transcranial magnetic stimulation continuous theta-burst stimulation
Description: cTBS
Study NCT03323255 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM repeated transcranial magnetic stimulation
Description: SHAM stimulation
Study NCT02479269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise for 8 weeks
Study NCT00331864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT04432974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic closed-loop anesthesia
Description: Total intravenous anesthesia performed with the ACTIVA automatic control system
Study NCT02937571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT02937571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02937571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03094988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and physical prehabilitation
Description: Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
Study NCT03094988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active attention control
Description: Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
Study NCT01355120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
Study NCT02600065 — intervention group
Intervention type: OTHER
Intervention: Blood draw and MRI
Description: The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
Study NCT03749291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obemat2.0 therapy
Description: Lifestyle (diet \& physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month \& 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight \& physical activity are defined to be accomplished until the next visit.
Study NCT03749291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinical Practice
Description: Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians \& nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity \[Spanish Ministry of Science and Innovation\], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
Study NCT02249520 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET-MR imaging on Biograph mMR scanner
Description: Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
Study NCT02249520 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MR-only imaging on Biograph mMR scanner
Description: Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
Study NCT02249520 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MR imaging on the Siemens Vida 3T MR scanner
Description: Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
Study NCT02547324 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Slump sitting
Description: Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
Study NCT02547324 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Forward bending
Description: Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 240mg + Rebamipide 200mg or Placebo
Description: Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SA001 240mg + Rebamipide 200mg or Placebo
Description: Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 240mg + Rebamipide 200mg or Placebo
Description: Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 480mg or Placebo
Description: Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 480mg or Placebo
Description: Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 710mg + Rebamipide 600mg or Placebo
Description: Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SA001 710mg + Rebamipide 600mg or Placebo
Description: Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 710mg + Rebamipide 600mg or Placebo
Description: Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 1,080mg or Placebo
Description: Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 1,080mg or Placebo
Description: Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 360mg or Placebo
Description: Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 360mg or Placebo
Description: Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 720mg or Placebo
Description: Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 720mg or Placebo
Description: Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA001 1,080mg or Placebo
Description: Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Study NCT05303961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA001 1,080mg or Placebo
Description: Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
Study NCT01745068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated program
Description: Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
Study NCT00785876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LRAR Implementation
Description: Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals.
Study NCT01321437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT01321437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01321437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
Study NCT01321437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01679431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler-echocardiography
Study NCT01679431 — intervention group
Intervention type: RADIATION
Intervention: Computed tomography
Study NCT01679431 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Study NCT01679431 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fasting blood sample
Study NCT01023776 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A/California/07/09 live monovalent H1N1 vaccine
Description: 0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
Study NCT02937363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Description: A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
Study NCT02937363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A trial of exercise before and after 4 weeks of placebo administration.
Study NCT04374188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: drug adminstration to ameliorate sepsis incidence
Study NCT04374188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: levofloxacin pill
Study NCT01086228 — intervention group
Intervention type: DEVICE
Intervention: XIENCE V / PROMUS stent
Description: Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
Study NCT02459886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: IV infusion
Study NCT02459886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study NCT00173888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin
Description: docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
Study NCT00173888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Cisplatin
Description: gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
Study NCT04295551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / ritonavir tablets combined with Xiyanping injection
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
Study NCT04295551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir treatment
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
Study NCT03591185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FallSensing Clinical Tool
Description: FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise.
Study NCT02687243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Application
Description: Online application via tablet
Study NCT02197234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291
Study NCT02197234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
Study NCT02197234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
Study NCT02197234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - simvastatin
Description: Blood sampling to measure simvastatin levels
Study NCT02197234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study NCT02512692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
Study NCT02512692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
Study NCT03491215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: All enrolled pediatric participants received ruxolitinib as a 5 mg tablet (adult and adolescent formulation) or an oral pediatric formulation (administered as oral solution or capsule dispersed in liquid).
Study NCT03835819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
Study NCT03835819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN853
Description: Mirvetuximab soravtansine is an antibody-drug conjugate.
Study NCT04638296 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
Study NCT02722486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation/Balance Belt
Description: With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
Study NCT02722486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vestibular Rehabilitation
Description: This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
Study NCT03098355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19/22 T cells
Description: CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
Study NCT03098355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
Study NCT01969643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladiratuzumab vedotin
Description: LV will be given into the vein (IV; intravenously)
Study NCT01969643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
Study NCT03644680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal Provocation with Birch Extract
Description: Nasal spray containing birch extract from Allergopharma
Study NCT03644680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Provocation with NaCl 0.9%
Description: Nasal spray containing sterile sodium chloride 0.9%
Study NCT04860427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trapezoidal condylar plate
Description: trapezoidal condylar plate open reduction and fixation
Study NCT04860427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two miniplates
Description: two miniplates open reduction and fixation
Study NCT06193525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
Study NCT02600351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT02600351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01961245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nocturnal non-invasive ventilation
Description: patients will undergo a non-invasive ventilation during the night
Study NCT01843309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg
Study NCT01843309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 200mg
Study NCT01843309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01565759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg.
Study NCT03162211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback Report
Description: There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.